SCHEMBL10004482

SCHEMBL10004482

Cc1ccc(S(=O)(=O)n2c(C(=O)C(C#N)=CN(C)C)cc3cc(C4CCN(C5CCCC5)CC4)ccc32)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALOX5 P09917 1/20 0.42
▸ DRD3 P35462 2/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ ALDH1A1 P00352 3/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ NOD2 Q9HC29 1/20 0.34
▸ NOD1 Q9Y239 1/20 0.34
▸ KDM2B Q8NHM5 3/20 0.34
▸ HTR6 P50406 3/20 0.34
▸ HTT P42858 1/20 0.33
▸ EBP Q15125 1/20 0.33
▸ DHCR7 Q9UBM7 1/20 0.33
▸ PPARG P37231 1/20 0.32
▸ PPARD Q03181 1/20 0.32
▸ USP5 P45974 1/20 0.32
▸ POLB P06746 1/20 0.32
▸ HRH1 P35367 1/20 0.32
▸ CCR3 P51677 1/20 0.32
▸ KCNH2 Q12809 1/20 0.32
▸ SLC18A3 Q16572 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10004481 1.00 ALOX5 (0.42) ALOX5DRD3SMN1; SMN2ALDH1A1KDM4E
SCHEMBL10004589 0.99 ALOX5 (0.41) ALOX5DRD3SMN1; SMN2ALDH1A1KDM4E
SCHEMBL10004574 0.99 ALOX5 (0.41) ALOX5DRD3SMN1; SMN2ALDH1A1KDM4E
SCHEMBL10004324 0.91 ALOX5 (0.43) ALOX5SMN1; SMN2ALDH1A1NOD2NOD1
SCHEMBL10004320 0.91 ALOX5 (0.43) ALOX5SMN1; SMN2ALDH1A1NOD2NOD1
SCHEMBL11905443 0.91 ALOX5 (0.42) ALOX5DRD3ALDH1A1KDM4ENOD2
SCHEMBL16188502 0.91 ALOX5 (0.42) ALOX5DRD3ALDH1A1KDM4ENOD2
SCHEMBL11905442 0.91 ALOX5 (0.42) ALOX5DRD3ALDH1A1KDM4ENOD2
SCHEMBL11929891 0.88 ALOX5 (0.40) ALOX5ALDH1A1NOD2NOD1PPARG
SCHEMBL10003494 0.88 ALOX5 (0.40) ALOX5ALDH1A1NOD2NOD1PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2471786-B1 AMINOPYRAZOLE DERIVATIVE CHUGAI PHARMACEUTICAL CO LTD (JP) 2015-11-04 — — EP disclosed
US-9102692-B2 Aminopyrazole derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-08-11 — — US disclosed
US-9102692-B2 Aminopyrazole derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-08-11 — — US disclosed
US-20140315856-A1 AMINOPYRAZOLE DERIVATIVE F. HOFFMANN-LA ROCHE AG (CH) 2014-10-23 — — US disclosed
US-20140315856-A1 AMINOPYRAZOLE DERIVATIVE F. HOFFMANN-LA ROCHE AG (CH) 2014-10-23 — — US disclosed
US-8829199-B2 Aminopyrazole derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2014-09-09 — — US disclosed
US-8829199-B2 Aminopyrazole derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2014-09-09 — — US disclosed
US-20120208811-A1 Aminopyrazole Derivative F. HOFFMANN-LA ROCHE AG (CH) 2012-08-16 — — US disclosed
US-20120208811-A1 Aminopyrazole Derivative F. HOFFMANN-LA ROCHE AG (CH) 2012-08-16 — — US disclosed
EP-2471786-A1 AMINOPYRAZOLE DERIVATIVE Chugai Seiyaku Kabushiki Kaisha (JP) 2012-07-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208811-A1 Aminopyrazole Derivative FGFR1, FGFR3, FGFR4 ALOX5 2600/4885DRD3 2923/4885SMN1; SMN2 4826/4885
US-20140315856-A1 AMINOPYRAZOLE DERIVATIVE H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, IL4I1, CYP3A43 ALOX5 643/4885DRD3 981/4885SMN1; SMN2 4605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback